

Contents

Preface	<i>XV</i>
A Personal Foreword	<i>XVII</i>
List of Contributors	<i>XIX</i>
I Introduction to MS in bioanalysis	<i>1</i>
1 Mass Spectrometry in Bioanalysis – Methods, Principles and Instrumentation	<i>3</i>
<i>Gérard Hopfgartner</i>	
1.1	Introduction <i>3</i>
1.2	Fundamentals <i>4</i>
1.3	Ionization Techniques <i>10</i>
1.3.1	Electron Impact and Chemical Ionization <i>10</i>
1.3.2	Atmospheric Pressure Ionization <i>12</i>
1.3.2.1	Electrospray <i>14</i>
1.3.2.2	Atmospheric Pressure Chemical Ionization <i>17</i>
1.3.2.3	Photoionization <i>19</i>
1.3.2.4	Multiple Ionization Source <i>19</i>
1.3.2.5	Desorption Electrospray and Direct Analysis in Real Time <i>20</i>
1.3.3	Matrix Assisted Laser Desorption Ionization <i>21</i>
1.4	Mass Analyzers <i>23</i>
1.4.1	Quadrupole Analyzers <i>23</i>
1.4.2	Triple Quadrupole Mass Analyzer <i>24</i>
1.4.3	Ion Trap Mass Spectrometry <i>27</i>
1.4.4	Triple Quadrupole Linear Ion Trap <i>30</i>
1.4.5	Time of Flight Mass Spectrometry <i>33</i>
1.4.6	Fourier Transform Mass Spectrometry <i>36</i>
1.4.6.1	Fourier Transform–Ion Cyclotron Resonance Mass Spectrometry <i>36</i>
1.4.6.2	Orbitrap Mass Spectrometer <i>37</i>
1.5	Ion Detectors <i>38</i>
1.6	Practical Aspects and Applications in Bioanalysis <i>41</i>

1.6.1	Introduction	41
1.6.2	Quantitative Analysis in Biological Matrices	42
1.6.3	Drug Metabolism	45
1.6.4	Analysis of Proteins	49
1.7	Perspectives	54
1.8	Common Definitions and Abbreviations	58
	<i>References</i>	58
II	Studying target-ligand interactions analyzing the ligand by MS	63
2	Drug Screening Using Gel Permeation Chromatography Spin Columns Coupled with ESI-MS	65
	<i>Marshall M. Siegel</i>	
2.1	Introduction	65
2.1.1	Preface	65
2.1.2	Direct and Indirect ESI-MS Analysis of Non-covalent Drug-Protein Complexes	65
2.1.3	Advantages of GPC Spin Columns	66
2.1.4	Application of Equilibrium and Non-equilibrium Theory for the Analysis of GPC Spin Column Eluates	68
2.1.4.1	Sample Prepared Under Equilibrium Conditions Prior to Spin Column Treatment	69
2.1.4.2	Calculation for Predicting the Concentration of Sample Complex Eluted From the Spin Column	69
2.1.4.3	Estimation of Relative Binding Affinities from GPC Spin-Column/ESI-MS Data	72
2.1.4.4	Experimental Determination of the K_d Value from GPC Spin-Column/ESI-MS Data	72
2.2	Experimental	73
2.2.1	Spin Columns	73
2.2.2	Spin Column Media: Advantages and Disadvantages, Volatile vs Non-volatile Buffers	74
2.2.3	Preparing Non-covalent Complexes in Protein Buffer; Protein Concentration, Ligand Concentration, Incubation Time	75
2.2.4	Sample Organization: Single Samples vs Mixtures, Mixture Set-up: Compatibility of Components, Plate Set-up	79
2.2.5	Pooling Spin Column Eluates for Higher Throughput	80
2.2.6	Manual vs Robotic Instrumentation for Sample Preparation and Acquiring Spin Column Eluates	80
2.2.7	ESI Mass Spectrometer: ESI, APCI, Photodissociation, Positive/Negative Ionization	81
2.2.8	ESI Multi-sprayer (MUX) Technology; Sample Throughput; Protein Consumption	82
2.2.9	Reversed Phase (RP) HPLC ESI-MS Considerations	83
2.2.10	Protein Removal for Optimum Sensitivity	84

2.2.11	Data Reduction and Automated Interpretation of GPC Spin Column/ESI-MS Data	84
2.3	Results	89
2.3.1	Secondary Screens	89
2.3.1.1	GPC Spin Column/ESI-MS Drug Screening Demonstration Papers	89
2.3.1.2	Estrogen Receptor Target	89
2.3.1.3	Non-covalent Binding of Drugs to RNA/DNA Targets	90
2.3.1.4	Amgen Secondary Screens	94
2.3.1.5	Novartis Secondary Screens	94
2.3.2	Primary Screens	94
2.3.2.1	RGS4 Protein Target	94
2.3.2.2	Amgen Primary Screens	98
2.3.2.3	Novartis Primary Screens	98
2.3.3	Additional Spin Column Methods	99
2.3.3.1	Competition Experiments of Inhibitor Mixture with Protein Target	99
2.3.3.2	GPC Spin Column/ESI-MS Determination of Binding Sites	101
2.3.3.3	Obtaining MS EC ₅₀ s and K _d s for Ligands Non-covalently Bound to Protein Active Sites	112
2.3.3.4	Multiple Passes Through Spin Columns – Finding Strongest Binders	113
2.3.3.5	Reverse Screening with GPC Spin Columns	113
2.4	Conclusions	113
2.4.1	GPC Spin Column/ESI-MS: Ease of Use, Mixture Analysis, High Speed, Reliability, Uncoupling of GPC from ESI-MS and HPLC ESI-MS	113
2.4.2	Comparison of GPC Spin Column/HPLC ESI-MS with Tandem Chromatographic Method of GPC/HPLC ESI-MS	114
2.4.3	Future Developments	115
2.4.3.1	MS and HPLC Improvements	115
2.4.3.2	Use of Automated Nanospray for Greater Sensitivity and Smaller Sample Size (Less Protein/Drug)	115
2.4.3.3	Microfluidic Systems: Sensitivity, High Speed	116
2.4.3.4	GPC Spin Column Eluates Analyzed by ESI/Ion Mobility/Mass Spectrometry	116
2.4.3.5	GPC Spin Columns with Matrixless MALDI-MS and Gyros GPC Microfluidic ESI/MALDI-MS System	116
	<i>References</i>	117
3	ALIS: An Affinity Selection–Mass Spectrometry System for the Discovery and Characterization of Protein–Ligand Interactions	121
	<i>Allen Annis, Cheng-Chi Chuang, and Naim Nazef</i>	
3.1	Introduction	121
3.1.1	State of the Art	122

3.1.1.1	Spectroscopic and Biophysical Methods	122
3.1.1.2	Mass Spectrometry-based Methods	123
3.2	ALIS: An Affinity Selection–Mass Spectrometry System based on Continuous SEC	124
3.2.1	ALIS System Design	126
3.3	Discovery of Ligands from Combinatorial Libraries	127
3.4	Quantitative Binding Affinity Measurement	130
3.4.1	Theory	131
3.4.2	Simulations and Experimental Results	134
3.5	Competition-based Binding Site Determination and Affinity Ranking in Mixtures	135
3.5.1	Binding Site Classification	136
3.5.2	Affinity Ranking in Compound Mixtures	140
3.6	Protein–Ligand Dissociation Rate Measurement	142
3.6.1	Theory	143
3.6.2	Simulations	145
3.6.3	Experimental Results	147
3.7	Conclusions	150
3.8	Future Directions	151
	<i>References</i>	152
4	Library Screening Using Ultrafiltration and Mass Spectrometry	157
	<i>Timothy E. Cloutier and Kenneth M. Comess</i>	
4.1	Introduction	157
4.2	Ultra-high Throughput Filtration-based Affinity Screening as a Discovery Tool	163
4.2.1	Affinity Selection/Mass Spectrometry	163
4.2.2	Primary Screening Strategy	164
4.2.3	Retesting and Deconvolution Strategy	167
4.2.4	Promiscuous Compound Filter	168
4.2.5	MurF Lead Discovery	171
4.3	Additional Affinity Screening Methodology That Includes Mass Spectrometry-based Readout	177
4.3.1	Pulsed Ultrafiltration MS	177
4.4	Conclusions and Future Directions	180
	<i>References</i>	181
5	Continuous-flow Systems for Ligand Binding and Enzyme Inhibition Assays Based on Mass Spectrometry	185
	<i>Hubertus Irth</i>	
5.1	Introduction	185
5.2	Continuous-flow Enzyme Assays Based on Mass Spectrometry	186

5.2.1	Assay Principle	186
5.2.2	ESI-MS Assay of Cathepsin B	188
5.2.2.1	MS Assay Development for Cathepsin B	188
5.2.2.2	Compatibility of Cathepsin B Assay with MS Detection	188
5.2.2.3	On-line Coupling of MS-based Cathepsin B Assay to HPLC	190
5.2.2.4	Screening of Natural Products for Cathepsin B Activity	192
5.2.3	ESI-MS Assay of Acetylcholinesterase	194
5.2.3.1	MS Assay Development for Acetylcholinesterase	194
5.2.3.2	Assay Validation and Stability	197
5.2.3.3	Screening of Natural Products for Acetylcholinesterase Activity	197
5.2.4	Miniaturization of Electrospray MS Assays	198
5.2.4.1	Chip-based Electrospray MS Assays	198
5.2.4.2	Chip Performance	199
5.2.4.3	Sensitivity of the Chip-based MS Screening System	200
5.3	Continuous-flow Ligand Binding Assays Based on Mass Spectrometry	200
5.3.1	Assay Principle	200
5.3.2	Optimization of MS Conditions	201
5.3.3	On-line Continuous-flow Biochemical Interaction	202
5.3.4	Monitoring Bioactive Compounds	204
5.3.5	Antibody–Antigen Interactions	205
5.3.6	Continuous-flow Multi-protein Binding Assays Using Electrospray MS	205
5.4	MS Assay Based on Dissociation of Isolated Protein–Ligand Complexes	207
5.4.1	Assay Set-up	207
5.4.2	Flow Injection Label-free MS Assay	209
5.4.3	Flow Injection Label-free MS Assay Screening of Natural Extracts	211
5.5	Future Prospects	211
	<i>References</i>	213

6 Frontal Affinity Chromatography – Mass Spectrometry for Ligand Discovery and Characterization 217

Nora Chan, Darren Lewis, Michele Kelly, Ella S.M. Ng, and David C. Schriemer

6.1	Introduction	217
6.1.1	The Basic Frontal Method	218
6.1.2	FAC – Basic Theory	220
6.1.3	FAC Advantages	221
6.1.4	FAC Disadvantages	223
6.2	Enabling FAC with MS Detection	224
6.2.1	Direct FAC-MS Methods for Compound Binding Data	224
6.2.2	Direct Method for Discovering and Ranking Multiple Ligands	226
6.2.3	Indirect Methods	232

6.3	System Advancements – Fluidics, Immobilization, Detection	235
6.3.1	Column	235
6.3.2	System	239
6.3.3	Breakthrough Curve Detection and Data Analysis	241
6.4	Select Applications	242
6.5	Summary and Evaluation	243
	<i>References</i>	244
7	MS Binding Assays – An Alternative to Radioligand Binding	247
	<i>Georg Höfner, Christine Zepperitz, and Klaus T. Wanner</i>	
7.1	Introduction	247
7.2	Radioligand Binding Assays	248
7.2.1	General Principle	248
7.2.1.1	Saturation Assays	248
7.2.1.2	Competition Assays	249
7.2.1.3	Kinetic Assays	250
7.2.2	Application	251
7.2.3	Disadvantages and Alternatives	252
7.3	MS Binding Assays	254
7.3.1	MS Binding Assays Quantifying the Nonbound Marker	255
7.3.1.1	Competition Assays for D ₁ and D ₂ Dopamine Receptors	257
7.3.1.2	Library Screening and Competition Assays for μ -Opioid Receptors	263
7.3.2	MS Binding Assays Quantifying the Bound Marker	267
7.3.2.1	Saturation Assays for mGAT1	268
7.3.2.2	Competition Assays for mGAT1	272
7.3.2.3	Kinetic Assays for mGAT1	272
7.4	Summary and Perspectives	276
	<i>References</i>	278
8	Laser Desorption Assays – MALDI-MS, DIOS-MS, and SAMDI-MS	285
	<i>Martin Vogel, Andy Scheffer, André Liesener, and Uwe Karst</i>	
8.1	MALDI-MS Assays	285
8.1.1	Principles of MALDI	285
8.1.2	Application of MALDI-MS in Bioanalysis	287
8.2	DIOS: Desorption/Ionization on Silicon	289
8.2.1	Principles of DIOS	289
8.2.2	Application of DIOS in Bioanalysis	292
8.3	SAMDI: Self-assembled Monolayers for MALDI-MS	295
8.3.1	Principles of SAMDI-MS	295
8.3.2	Application of SAMDI in Bioanalysis	297
8.4	Conclusion	299
	<i>References</i>	300

III	Studying target-ligand interactions analyzing intact target-ligand complexes by MS	303
9	Tethering: Fragment-based Drug Discovery by Mass Spectrometry	305
	<i>Mark T. Cancilla and Daniel A. Erlanson</i>	
9.1	Introduction	305
9.2	Reduction to Practice	307
9.2.1	Technique	307
9.2.2	Advantages	310
9.3	Finding Fragments: Thymidylate Synthase Proof of Principle	310
9.4	Finding and Linking Fragments in One Step: Tethering with Extenders	312
9.4.1	Caspase-3	312
9.4.2	Caspase-1	316
9.5	Conclusions	316
	<i>References</i>	<i>318</i>
10	Interrogation of Noncovalent Complexes by ESI-MS: A Powerful Platform for High Throughput Drug Discovery	321
	<i>Steven A. Hofstadler and Kristin A. Sannes-Lowery</i>	
10.1	Analysis of Noncovalent Complexes by ESI-MS	321
10.1.1	Solution Conditions	321
10.1.2	Proteins	322
10.1.3	Oligonucleotides	323
10.2	Multitarget Affinity/Specificity Screening	328
10.3	Multitarget Affinity/Specificity Screening in a High Throughput Format	329
10.4	Affinity/Specificity	330
10.5	SAR by MS	332
10.6	Future Directions	333
	<i>References</i>	<i>335</i>
IV	Studying target-ligand interactions analyzing the target binding site by MS	339
11	Quantification of Protein–Ligand Interactions in Solution by Hydrogen/Deuterium Exchange (PLIMSTEX)	341
	<i>Mei M. Zhu, David Hambly, and Michael L. Gross</i>	
11.1	Introduction	341
11.2	The PLIMSTEX Method	342
11.2.1	A General Protocol of H/D Exchange and LC/MS Analysis for PLIMSTEX	342

11.2.2	Determination and Interpretation of the Titration Curves	343
11.3	Applications of PLIMSTEX	345
11.3.1	Determination of Association Constant (K_a), Stoichiometry (n), and Protection (ΔD_i)	345
11.3.2	Ras-GDP Interacting with Mg^{2+} : A 1:1 Protein:Metal Ion Interaction	347
11.3.2.1	Kinetic Study of Forward H/D Exchange Ras-GDP with Different $[Mg^{2+}]$	347
11.3.2.2	PLIMSTEX Results for Ras-GDP Titrated with Mg^{2+}	348
11.3.2.3	Interpretation of PLIMSTEX Results with H/D Exchange Kinetics	349
11.3.2.4	Application of PLIMSTEX to Relatively Weak Protein–Ligand Binding	350
11.3.2.5	Experimental Issues Regarding Using Metal Chelators	350
11.3.3	Apo-CaM Interacting with Ca^{2+} : A 1:4 Protein:Metal Ion Interaction	351
11.3.3.1	PLIMSTEX Results for CaM and Intermediate Protein–Ligand Binding Species	351
11.3.3.2	PLIMSTEX in Biologically Relevant Media and High Ionic Strength	352
11.3.4	Apo-IFABP and Oleate: A Protein–Small Organic Molecule Interaction	353
11.3.5	Holo-CaM and Melittin: A Protein–Peptide Interaction	354
11.3.5.1	PLIMSTEX Curves Under Different Holo-CaM Concentrations	355
11.3.6	Self-association of Insulin: A Protein–Protein Interaction	356
11.3.6.1	Modified Version of PLIMSTEX for Insulin Self-association	356
11.4	Features of PLIMSTEX	357
11.4.1	Determines K_i , Stoichiometry, and Protection (ΔD_i)	357
11.4.2	Requires Low Quantities of Protein	357
11.4.3	Relies Only on MS to Measure m/z And Not Solution Concentration	358
11.4.4	Works in Biologically Relevant Media at High Ionic Strength	359
11.4.5	Does Not Need Specially Labeled Protein or Ligand	359
11.4.6	Avoids Perturbation of the Binding Equilibrium	360
11.4.7	Has Potential for Peptide Resolution	360
11.4.8	Current Challenges and Future Directions	360
11.5	Fast Radical Footprinting for Protein–Ligand Interaction Analysis	361
11.5.1	Rationale for Hydroxyl Radicals as a Probe	362
11.5.2	Methods for Generating Hydroxyl Radicals	362
11.5.3	Fast Photochemical Oxidation of Proteins	363
11.5.4	Locating the Sites of Oxidation	364
11.5.5	Application of FPOP to Apomyoglobin	364
11.5.6	Advantages of FPOP	366

11.6	Potential Applications in Drug Discovery	367
	<i>References</i>	368
12	Protein-targeting Drug Discovery Guided by Hydrogen/Deuterium Exchange Mass Spectrometry (DXMS)	377
	<i>Yoshitomo Hamuro, Stephen J. Coales, and Virgil L. Woods Jr</i>	
12.1	Introduction	377
12.2	Theory of H/D Exchange	378
12.2.1	Amide H/D Exchange	378
12.2.2	Protection Factor	378
12.2.3	Backbone Amide Hydrogens as Thermodynamic Sensors	379
12.3	Overview of H/D Exchange Technologies	380
12.3.1	On Exchange Reaction	380
12.3.2	Quench of Exchange Reaction	380
12.3.3	Protein Fragmentation by Proteolysis	381
12.3.4	Digestion Optimization	381
12.3.5	HPLC Separation	381
12.3.6	Mass Analysis	381
12.3.7	Automation of H/D Exchange by MS	382
12.3.8	Automated Data Analysis	383
12.4	DXMS-guided Design of Well Crystallizing Proteins	383
12.4.1	Disordered Regions and Protein Crystallography	383
12.4.2	Poorly Crystallizing Proteins Contain Substantial Disordered Regions	384
12.4.3	Disorder-depleted Mutant Preserved Ordered Structure	384
12.4.4	Disorder-depleted Mutant Improved Crystallization Efficiency and Produced High Resolution Structure	384
12.5	Rapid Characterization of Protein Conformational Change with DXMS	385
12.5.1	Human Growth Hormone	386
12.5.2	H/D Exchange of hGH	386
12.5.3	Free Energy Change upon Folding of hGH	386
12.6	Application of H/D Exchange to Protein–Small Molecule Ligand Interactions	388
12.6.1	p38 Mitogen-activated Protein Kinase	388
12.6.2	H/D Exchange of p38 MAP Kinase	389
12.6.3	Peroxisome Proliferator-activated Receptor γ	390
12.6.4	H/D Exchange of PPAR γ	390
12.7	DXMS-guided Design of Small Molecules that Target Protein–Protein Interaction Surfaces	391
12.8	Optimal Formulation and Quality Control of Whole-protein Therapeutics with DXMS	393
12.9	Conclusions	394
	<i>References</i>	394

V MS in early pharmacokinetics 399

13 Mass Spectrometry in Early Pharmacokinetic Investigations 401

Walter A. Korfmacher

13.1 Introduction 401

13.2 HPLC-MS/MS Overview 402

13.3 *In Vitro* Applications 405

13.4 *In Vivo* Applications 406

13.5 Rapid Method Development 408

13.6 Increasing Throughput in HPLC-MS/MS 410

13.7 Matrix Effects 411

13.8 Discovery PK Assay Rules 413

13.9 New Technology in LC-MS 415

13.10 Conclusion 419

References 419

Index 429